Equities

Exact Therapeutics AS

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Exact Therapeutics AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)2.70
  • Today's Change-0.14 / -4.93%
  • Shares traded55.45k
  • 1 Year change--
  • Beta0.0569
Data delayed at least 15 minutes, as of Jul 01 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-52.33m
  • Incorporated2012
  • Employees12.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lifecare ASA9.67m-71.76m107.89m33.00--1.21--11.16-16.93-16.930.87474.670.0972--3.11293,029.10-73.12-52.64-91.57-61.98-----752.26-277.39----0.1898---26.1036.13-103.52------
Abera Bioscience AB0.00-774.39k110.08m5.00--11.96-----0.0453-0.04530.000.56450.00----0.00-6.24-68.96-8.13-85.65------------0.00------93.42------
NextCell Pharma AB10.79m-40.70m117.97m24.00--1.42--10.93-0.6061-0.60610.15470.70270.153949.194.79423,385.40-58.04-35.01-66.62-37.45-223.34-304.79-377.03-468.526.78--0.00--5.4542.54-5.40---27.06--
Biosergen AB0.00-18.54m119.23m2.00--2.59-----0.1056-0.10560.000.18490.00----0.00-47.93---53.83--------------0.00------29.00------
IDL Diagnostics AB (publ)63.67m-46.99m122.35m22.00--1.06--1.92-0.192-0.1920.26020.47260.41717.136.152,724,546.00-30.78-29.04-33.76-31.1420.131.70-73.80-157.604.24--0.00--33.45164.6228.41--18.85--
Spago Nanomedical AB (publ)2.02m-34.18m124.65m9.00--4.59--61.79-0.1002-0.10020.00580.07350.0529--14.12146,076.90-89.69-24.44-106.09-25.71-----1,694.63-3,325.49----0.00--58.85129.5223.01------
Klaria Pharma Holding AB (publ)11.93m-44.86m135.93m4.00--36.55--11.39-0.3273-0.29220.08430.01140.1819--5.922,808,250.00-68.37-48.20-268.00-74.06-----375.93-1,522.52---1.510.2672---73.41-11.85-33.44------
Dextech Medical AB0.00-4.92m141.39m1.00--5.07-----0.2506-0.25060.001.420.00----0.00-15.82-23.30-16.21-23.93------------0.00-------2.51--18.92--
Lumito AB (publ)86.59k-49.13m155.07m10.00--1.80--1,790.92-0.1668-0.16680.00030.30460.0008-3.738.586,792.50-43.35-24.12-52.27-26.463,028.34---56,746.39-138,894.000.9001-15.420.1337-------61.08---30.66--
Exact Therapeutics AS0.00-52.33m170.81m12.00--1.48-----1.53-1.530.001.830.00----0.00-48.79-43.50-64.83-50.76------------0.0056-------8.27--1.47--
Alzinova AB105.16k-22.59m177.31m5.00--1.21--1,686.04-0.2707-0.27070.00121.320.0008--0.154719,800.00-17.38-12.21-18.61-12.85-9,586.87---21,481.82-21,390.81---575.220.0067---88.89---24.71--19.48--
Glycorex Transplantation AB (publ)39.05m-9.65m178.25m20.00--4.31592.944.56-0.122-0.1220.49220.51460.62161.265.201,838,200.00-15.35-15.79-20.28-18.6680.8887.06-24.70-44.851.59-14.760.1227--17.35-0.529663.97------
SenzaGen AB60.57m-20.07m179.27m36.00--2.09--2.96-0.6761-0.67611.992.740.59183.716.171,676,912.00-19.61-20.91-25.12-25.1767.0167.10-33.13-71.432.78--0.0176--15.6984.1619.22---1.18--
Medivir AB3.81m-117.40m188.98m10.00--1.73--49.64-0.9658-0.96580.03130.91480.0175--0.8239358,400.00-53.86-31.75-66.42-38.14-----3,083.62-740.12----0.0723---54.36-16.77-38.06------
Annexin Pharmaceuticals AB (publ)0.00-48.62m204.71m4.00--4.21-----10.08-10.080.006.480.00----0.00-153.01-145.61-185.94-179.48------------0.00-------14.07------
Kancera AB0.00-47.30m212.41m5.00--4.05-----0.3675-0.36750.000.40740.00----0.00-49.50-54.11-62.16-63.47--70.00---275,694.40----0.00------31.32------
Data as of Jul 01 2025. Currency figures normalised to Exact Therapeutics AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

3.11%Per cent of shares held by top holders
HolderShares% Held
Nordea Funds Ltd.as of 30 Apr 20251.24m1.97%
Danske Invest Asset Management ASas of 30 May 2025719.11k1.14%
Data from 30 Apr 2025 - 31 May 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.